Catalyst Event
AbbVie Inc (ABBV) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
3/17/2026, 12:00:00 AM
The FDA rejected Aldeyra Therapeutics' dry eye disease drug, reproxalap, for which AbbVie holds an exclusive commercialization option, citing a lack of substantial evidence of efficacy.
Korean Translation
AbbVie가 독점 상업화 옵션을 보유한 Aldeyra Therapeutics의 안구건조증 치료제 레프록살랍이 효능에 대한 실질적인 증거 부족을 이유로 FDA의 승인을 받지 못함.
Related Recent Events
Alphabet Inc (GOOGL) · Other
Google I/O 2026 developer conference is scheduled for 2026-05-19. Developer conferences usually have a 1-5% price impact. Updates on AI, Gemini, and Android are expected.
5/19/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Earnings Release
Q1 2026 earnings release is scheduled for 2026-05-11. Analysts forecast revenue between $600M-$625M and adjusted EBITDA of $35M-$55M. Low importance is estimated as the market typically anticipates scheduled earnings results, which is forecasted.
5/11/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
First quarter 2026 earnings results and conference call scheduled.
5/5/2026, 12:00:00 AM
Tempus AI Inc (TEM) · Earnings Release
Q1 2026 earnings release on May 5, 2026, with low importance estimated as the date is unconfirmed, expected.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast EPS around $7.25-$7.50 estimated. High importance estimated due to the significant weight of earnings reports on stock volatility.
4/30/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
First quarter 2026 earnings release; importance is estimated as Medium because quarterly earnings reports often result in price movements exceeding 5%, scheduled.
4/24/2026, 12:00:00 AM